Establishment Labs Q3 revenue $38.5M (+0.8% YoY); net loss widens to $29.3M; cuts 2023 guidance to ~$165M

ESTABLISHMENT LABS HOLDINGS INC.

2023-Q3 EPS reported -$2.28 revenue$133,591,000

Revenue $38.5M (+0.8% YoY); net loss $29.3M vs $18.6M; operating loss $21.0M vs $10.5M.
2023 revenue guidance lowered to ~$165M (up 2% over 2022); China approval removed from forecasts.
Cash $52.2M at Sep 30; cash burn $14.2M since Dec 31, partially offset by Apr follow-on offering.
FDA clearance of Motiva Flora SmoothSilk Tissue Expander on Oct 13; Mia Femtech 2-year data shows no capsular contracture.
Reaffirms $500M revenue target for 2026 despite near-term demand softness.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ESTABLISHMENT LABS HOLDINGS INC. reported third quarter ended September 30, 2023 results: revenue $38.5 million. Guidance lowered.

Period: third quarter ended September 30, 2023
Revenue: $38.5 million
Guidance: lowered
Result: reported results

Exact text from the filing

and reconstruction, today announced financial results for the third quarter ended September 30, 2023. Third Quarter Highlights and Outlook • Third quarter worldwide revenue of $38.5 million increased 0.8% year-over-year. • 2023 revenue guidance updated to approximately $165 million, an increase of 2% over 2022. • Third quarter loss from operations was $21.0 million

View on SEC.gov

Browse all earnings releases →

ESTABLISHMENT LABS HOLDINGS INC. filing history →

Source: SEC EDGAR

accession 0001688757-23-000079

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.